IL144964A0 - Methods of treatment of mitochondrial disorders - Google Patents
Methods of treatment of mitochondrial disordersInfo
- Publication number
- IL144964A0 IL144964A0 IL14496400A IL14496400A IL144964A0 IL 144964 A0 IL144964 A0 IL 144964A0 IL 14496400 A IL14496400 A IL 14496400A IL 14496400 A IL14496400 A IL 14496400A IL 144964 A0 IL144964 A0 IL 144964A0
- Authority
- IL
- Israel
- Prior art keywords
- methods
- mitochondrial disorders
- treatment
- mitochondrial
- disorders
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 208000012268 mitochondrial disease Diseases 0.000 title abstract 4
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 239000002777 nucleoside Substances 0.000 abstract 1
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract 1
- 150000003230 pyrimidines Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- -1 triacetyluridine Chemical class 0.000 abstract 1
- AUFUWRKPQLGTGF-FMKGYKFTSA-N uridine triacetate Chemical compound CC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@H](COC(=O)C)O[C@H]1N1C(=O)NC(=O)C=C1 AUFUWRKPQLGTGF-FMKGYKFTSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12158899P | 1999-02-23 | 1999-02-23 | |
| PCT/US2000/004663 WO2000050043A1 (en) | 1999-02-23 | 2000-02-23 | Methods of treatment of mitochondrial disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL144964A0 true IL144964A0 (en) | 2002-06-30 |
Family
ID=22397641
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL14496400A IL144964A0 (en) | 1999-02-23 | 2000-02-23 | Methods of treatment of mitochondrial disorders |
| IL144964A IL144964A (en) | 1999-02-23 | 2001-08-19 | Medicines to treat deficiencies of pyrimidine synthesis pathways, containing 2 ', 3', 5 'triacetylauridine |
| IL180528A IL180528A (en) | 1999-02-23 | 2007-01-03 | Pharmaceuticals containing certain uridine derivatives |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL144964A IL144964A (en) | 1999-02-23 | 2001-08-19 | Medicines to treat deficiencies of pyrimidine synthesis pathways, containing 2 ', 3', 5 'triacetylauridine |
| IL180528A IL180528A (en) | 1999-02-23 | 2007-01-03 | Pharmaceuticals containing certain uridine derivatives |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US7638501B1 (enExample) |
| EP (2) | EP1171137B1 (enExample) |
| JP (1) | JP4776780B2 (enExample) |
| KR (2) | KR100879559B1 (enExample) |
| CN (2) | CN1191835C (enExample) |
| AT (1) | ATE381935T1 (enExample) |
| AU (1) | AU776437B2 (enExample) |
| BR (1) | BR0008447A (enExample) |
| CA (1) | CA2362925C (enExample) |
| DE (1) | DE60037578T2 (enExample) |
| DK (1) | DK1171137T3 (enExample) |
| ES (1) | ES2298130T3 (enExample) |
| HU (1) | HU230191B1 (enExample) |
| IL (3) | IL144964A0 (enExample) |
| MX (1) | MXPA01008549A (enExample) |
| NZ (1) | NZ513926A (enExample) |
| PT (1) | PT1171137E (enExample) |
| RU (2) | RU2268732C2 (enExample) |
| WO (1) | WO2000050043A1 (enExample) |
| ZA (1) | ZA200107727B (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6306909B1 (en) | 1997-03-12 | 2001-10-23 | Queen's University At Kingston | Anti-epileptogenic agents |
| US8143234B2 (en) * | 1998-07-31 | 2012-03-27 | Massachusetts Institute Of Technology | Uridine administration improves phosphatide synthesis, synaptic transmission and cognitive function |
| US8518882B2 (en) * | 1998-07-31 | 2013-08-27 | Massachusetts Institute Of Technology | Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same |
| US20050203053A1 (en) * | 1999-07-30 | 2005-09-15 | Wurtman Richard J. | Uridine administration improves phosphatide synthesis, synaptic transmission and cogntive function |
| US6989376B2 (en) * | 1998-07-31 | 2006-01-24 | Massachusetts Institute Of Technology | Methods for increasing blood cytidine and/or uridine levels and treating cytidine-dependent human diseases |
| US8314064B2 (en) * | 1998-07-31 | 2012-11-20 | Massachusetts Institute Of Technology | Uridine administration stimulates membrane production |
| US7807654B2 (en) | 1998-08-31 | 2010-10-05 | Wellstat Therapeutics Corporation | Compositions and methods for treatment of mitochondrial diseases |
| US6472378B2 (en) | 1998-08-31 | 2002-10-29 | Pro-Neuron, Inc. | Compositions and methods for treatment of mitochondrial diseases |
| US7915233B1 (en) | 1998-08-31 | 2011-03-29 | Wellstat Therapeutics Corporation | Compositions and methods for treatment of mitochondrial diseases |
| KR100879559B1 (ko) | 1999-02-23 | 2009-01-22 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 미토콘드리아 장애의 치료 또는 예방용 제약조성물 |
| US6727231B1 (en) * | 2000-10-12 | 2004-04-27 | Repligen Corporation | Uridine therapy for patients with elevated purine levels |
| DE10110355A1 (de) | 2001-03-03 | 2002-09-12 | Ulrich Walker | Bekämpfung von Nebenwirkungen |
| EP1385831A2 (en) * | 2001-04-11 | 2004-02-04 | Queen's University At Kingston | Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents |
| JP4105626B2 (ja) * | 2001-05-29 | 2008-06-25 | ザ ユニバーシティ オブ ブリティッシュ コロンビア | ミトコンドリアｄｎａアッセイの薬理学的応用 |
| JP2004182705A (ja) * | 2002-10-11 | 2004-07-02 | Yasutoshi Koga | ミトコンドリア機能異常に起因する疾患における臨床症状発現の予防・治療用組成物 |
| AU2004209522A1 (en) * | 2003-01-17 | 2004-08-19 | Gilead Palo Alto, Inc. | Substituted heterocyclic compounds useful in the treatment of cardiovascular diseases |
| WO2006130775A2 (en) | 2005-06-01 | 2006-12-07 | Edison Pharmaceuticals, Inc. | Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomakers |
| PT1933821T (pt) * | 2005-09-15 | 2020-10-15 | Ptc Therapeutics Inc | Variantes de cauda de terapêuticos redox-ativos para tratamento de doenças mitocondriais e outras condições e modulação de biomarcadores energéticos |
| JP5374162B2 (ja) | 2006-02-22 | 2013-12-25 | エジソン ファーマシューティカルズ， インコーポレイテッド | ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節 |
| US8748405B2 (en) | 2007-01-26 | 2014-06-10 | City Of Hope | Methods and compositions for the treatment of cancer or other diseases |
| EP2217075A4 (en) | 2007-11-02 | 2012-01-25 | Massachusetts Inst Technology | URIDINE FOOD ADDITIONAL AGREEMENT PROCESS AND USE THEREOF |
| CN101612110B (zh) * | 2008-06-23 | 2012-07-25 | 欣凯医药化工中间体（上海）有限公司 | 三乙酰尿苷缓释制剂及其制备方法 |
| EP3827815B1 (en) | 2008-09-10 | 2023-09-06 | PTC Therapeutics, Inc. | Treatment of pervasive developmental disorders with redox-active therapeutics |
| RU2400221C2 (ru) * | 2008-11-11 | 2010-09-27 | ФГУ "Московский НИИ педиатрии и детской хирургии Росмедтехнологий" | Способ лечения врожденных структурных миопатий и врожденных мышечных дистрофий путем коррекции вторичных митохондриальных изменений |
| ES2640485T3 (es) * | 2011-08-12 | 2017-11-03 | Universitätsklinikum Freiburg | Uridina y análogos de uridina para el uso en el tratamiento de la enfermedad pulmonar obstructiva crónica |
| WO2015106255A1 (en) | 2014-01-13 | 2015-07-16 | City Of Hope | Multivalent oligonucleotide assemblies |
| DK3182980T3 (da) * | 2014-08-19 | 2021-01-11 | Wellstat Therapeutics Corp | Behandling af glykosyleringsmangelsygdomme |
| FR3027804A1 (fr) * | 2014-10-31 | 2016-05-06 | Centre Nat Rech Scient | Utilisation d'un inhibiteur de transcriptase inverse dans la prevention et le traitement des maladies degeneratives |
| BR112017022578A2 (pt) | 2015-05-29 | 2018-07-17 | The Board Of Trustees Of The Leland Stanford Junior University | agentes nucleosídicos para a redução da atividade deletéria de genes que contém repetições estendidas de nucleotídeos |
| PL3302499T3 (pl) * | 2015-06-05 | 2023-07-24 | Fundació Hospital Universitari Vall D'hebron - Institut De Recerca | Leczenie chorób mitochondrialnych |
| US10471087B2 (en) * | 2015-06-17 | 2019-11-12 | The Trustees Of Columbia University In The City Of New York | Deoxynucleoside therapy for diseases caused by unbalanced nucleotide pools including mitochondrial DNA depletion syndromes |
| US10703701B2 (en) | 2015-12-17 | 2020-07-07 | Ptc Therapeutics, Inc. | Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
| KR101981843B1 (ko) | 2016-09-13 | 2019-05-23 | 울산대학교 산학협력단 | 일산화탄소 또는 일산화탄소 공급체를 유효성분으로 함유하는 미토콘드리아 기능 개선용 조성물 |
| AU2019242628A1 (en) | 2018-03-26 | 2020-09-24 | Clear Creek Bio, Inc. | Compositions and methods for inhibiting dihydroorotate dehydrogenase |
| CN114340641B (zh) * | 2019-09-05 | 2025-04-04 | 米托瑞因博治疗股份有限公司 | 治疗线粒体dna缺失障碍 |
| US12076315B2 (en) | 2020-03-20 | 2024-09-03 | Clear Creek Bio, Inc. | Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof |
| KR102290596B1 (ko) * | 2020-09-10 | 2021-08-19 | 주식회사 파이안바이오테크놀로지 | 분리된 미토콘드리아를 포함하는 주사용 조성물 및 이의 용도 |
| KR20230067613A (ko) * | 2020-09-14 | 2023-05-16 | 웰스태트 테러퓨틱스 코포레이션 | 5' 위치에서 아세토아세틸로 치환된 2',3'-디아세틸우리딘 |
| EP3970713A1 (en) | 2020-09-16 | 2022-03-23 | GV Squared S.r.l. | Pharmaceutical composition comprising uridine and pyruvate for regulating the profileration, activity and survival of immune cells |
| CN113116900B (zh) * | 2021-04-14 | 2022-07-08 | 兰州大学 | 一类核苷类似物在制备预防和/或治疗脑血管疾病药物中的应用 |
| BE1030026B1 (fr) * | 2022-06-14 | 2023-07-07 | Dendrogenix | Composés dérivés de stérols et composition pharmaceutique les comprenant pour leur utilisation dans la prévention, l’amélioration et/ou le traitement d’une pathologie liée à un déficit mitochondrial |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5A (en) * | 1836-08-10 | Thomas Blanchard | Machine for mortising solid wooden shells of ships' tackle-blocks | |
| JPS5356690A (en) * | 1976-09-30 | 1978-05-23 | Rikagaku Kenkyusho | Purin compund sugar derivatives and their preparation |
| US7173017B1 (en) | 1987-10-28 | 2007-02-06 | Wellstat Therapeutics Corporation | Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis |
| JP2894610B2 (ja) * | 1987-10-28 | 1999-05-24 | プロ−ニューロン，インコーポレーテッド | アシル化ウリジンおよびシチジンならびにその使用 |
| US6348451B1 (en) | 1987-10-28 | 2002-02-19 | Pro-Neuron, Inc. | Acyl deoxyribonucleoside derivatives and uses thereof |
| US7307166B1 (en) | 1987-10-28 | 2007-12-11 | Wellstat Therapeutics Corporation | Oxpurine nucleosides and their congeners, and acyl, derivatives thereof, for improvement of hematopoiesis |
| US6743782B1 (en) | 1987-10-28 | 2004-06-01 | Wellstat Therapeutics Corporation | Acyl deoxyribonucleoside derivatives and uses thereof |
| US5736531A (en) | 1987-10-28 | 1998-04-07 | Pro-Neuron, Inc. | Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides |
| US5968914A (en) | 1987-10-28 | 1999-10-19 | Pro-Neuron, Inc. | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
| US6329350B1 (en) | 1987-10-28 | 2001-12-11 | Pro-Neuron, Inc. | Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis |
| US5470838A (en) | 1987-10-28 | 1995-11-28 | Pro-Neuron, Inc. | Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine |
| US6020322A (en) | 1993-11-09 | 2000-02-01 | Pro-Neuron, Inc. | Acyl deoxyribonucleoside derivatives and uses thereof |
| ATE243039T1 (de) | 1987-10-28 | 2003-07-15 | Wellstat Therapeutics Corp | Acyldeoxyribonukleosid-derivate und verwendungen davon |
| IT1219667B (it) | 1988-06-21 | 1990-05-24 | Polifarma Spa | Impiego di uridina nel trattamento farmacologico di disturbi dovuti ad alterato equilibrio dopaminergico |
| DE3843241A1 (de) * | 1988-12-22 | 1990-06-28 | Skrezek Christian | Nephroprotektive infusionsloesung |
| IT1241984B (it) | 1990-06-13 | 1994-02-02 | Polifarma Spa | Impiego di uridina nel trattamento farmacologico delle complicazioni periferiche del diabete |
| ES2224098T3 (es) * | 1992-05-28 | 2005-03-01 | Centre For Molecular Biology And Medicine, | Derivados de quinona para aumentar la bioenergia celular. |
| US5567689A (en) | 1993-08-13 | 1996-10-22 | The Uab Research Foundation | Methods for increasing uridine levels with L-nucleosides |
| US5852000A (en) | 1993-08-25 | 1998-12-22 | Otsuka Pharmaceutical Factory, Inc. | Cardiac rehabilitation agent |
| AU705230B2 (en) * | 1994-03-30 | 1999-05-20 | Mitokor | Diagnosis, therapy and cellular and animal models for diseases associated with mitochondrial defects |
| JP3808121B2 (ja) * | 1995-01-09 | 2006-08-09 | 日本メジフィジックス株式会社 | 低酸素症またはミトコンドリア機能障害診断剤 |
| US5962459A (en) | 1996-05-28 | 1999-10-05 | Polifarma S.P.A. | Therapeutic active agent for treatment of neuron degenerative diseases |
| JPH10273469A (ja) * | 1997-02-03 | 1998-10-13 | Takeda Chem Ind Ltd | ２環性キノン誘導体、製造法および剤 |
| US6472378B2 (en) | 1998-08-31 | 2002-10-29 | Pro-Neuron, Inc. | Compositions and methods for treatment of mitochondrial diseases |
| US7807654B2 (en) | 1998-08-31 | 2010-10-05 | Wellstat Therapeutics Corporation | Compositions and methods for treatment of mitochondrial diseases |
| KR100879559B1 (ko) | 1999-02-23 | 2009-01-22 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 미토콘드리아 장애의 치료 또는 예방용 제약조성물 |
-
2000
- 2000-02-23 KR KR1020077012846A patent/KR100879559B1/ko not_active Expired - Fee Related
- 2000-02-23 ES ES00910321T patent/ES2298130T3/es not_active Expired - Lifetime
- 2000-02-23 WO PCT/US2000/004663 patent/WO2000050043A1/en not_active Ceased
- 2000-02-23 BR BR0008447-6A patent/BR0008447A/pt not_active Application Discontinuation
- 2000-02-23 DK DK00910321T patent/DK1171137T3/da active
- 2000-02-23 AT AT00910321T patent/ATE381935T1/de active
- 2000-02-23 DE DE60037578T patent/DE60037578T2/de not_active Expired - Lifetime
- 2000-02-23 RU RU2001125913/14A patent/RU2268732C2/ru not_active IP Right Cessation
- 2000-02-23 EP EP00910321A patent/EP1171137B1/en not_active Expired - Lifetime
- 2000-02-23 KR KR1020017010801A patent/KR100758712B1/ko not_active Expired - Fee Related
- 2000-02-23 NZ NZ513926A patent/NZ513926A/en not_active IP Right Cessation
- 2000-02-23 JP JP2000600654A patent/JP4776780B2/ja not_active Expired - Lifetime
- 2000-02-23 EP EP07008953.7A patent/EP1808177B1/en not_active Expired - Lifetime
- 2000-02-23 PT PT00910321T patent/PT1171137E/pt unknown
- 2000-02-23 CA CA2362925A patent/CA2362925C/en not_active Expired - Fee Related
- 2000-02-23 HU HU0400914A patent/HU230191B1/hu not_active IP Right Cessation
- 2000-02-23 MX MXPA01008549A patent/MXPA01008549A/es active IP Right Grant
- 2000-02-23 CN CNB008041032A patent/CN1191835C/zh not_active Expired - Fee Related
- 2000-02-23 US US09/889,251 patent/US7638501B1/en not_active Expired - Fee Related
- 2000-02-23 RU RU2005121711/14A patent/RU2394580C2/ru not_active IP Right Cessation
- 2000-02-23 AU AU32434/00A patent/AU776437B2/en not_active Ceased
- 2000-02-23 CN CNB2004100784053A patent/CN100379426C/zh not_active Expired - Fee Related
- 2000-02-23 IL IL14496400A patent/IL144964A0/xx unknown
-
2001
- 2001-08-19 IL IL144964A patent/IL144964A/en not_active IP Right Cessation
- 2001-09-19 ZA ZA200107727A patent/ZA200107727B/en unknown
-
2007
- 2007-01-03 IL IL180528A patent/IL180528A/en not_active IP Right Cessation
-
2009
- 2009-12-21 US US12/643,920 patent/US8748408B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL144964A0 (en) | Methods of treatment of mitochondrial disorders | |
| FR13C0062I1 (enExample) | ||
| ATE225341T1 (de) | In 6-position durch thio substituierte paclitaxele | |
| AU2003272285A8 (en) | Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands | |
| BRPI0415699A (pt) | uso de oligossacarìdeo ácido e de oligossacarìdeo neutro, e, composições alimentìcia e lìquida | |
| ZA200108530B (en) | 4,5,6,7-tetrahydroindazole derivatives as antitumor agents. | |
| YU76100A (sh) | Pirolo(2,3-d) pirimidin preparati i njihova primena | |
| TW200503719A (en) | Pyridino [1,2-a] pyrimidin-4-one compounds as anticancer agents | |
| MY145074A (en) | Thiazolidin-4-one derivatives | |
| EP1767197A3 (en) | Treatment of Alzheimer's disease with inhibitors of cell cycle re-entry and progression | |
| YU60900A (sh) | Novi kristalni oblici antivirusnog benzimidazolskog jedinjenja | |
| ATE439363T1 (de) | Imidazo 2,1-b -1,3,4-thiadiazole sulfonamides | |
| TR200102008T2 (tr) | Serebral işemi profilaksı ve tedavisi için piridin türevlerinin kullanımı. | |
| DK1220852T3 (da) | Substituerede diazepaner | |
| AU1171102A (en) | Uridine therapy for patients with elevated purine levels | |
| NO933722L (no) | Pyrimidin-derivater for forbedring av antitumor-aktivitet | |
| WO2001057042A3 (de) | 4-pyridyl- und 2,4-pyrimidinyl-substituierte pyrrolderivate und ihre anwendung in der pharmazie | |
| BR0101245B1 (pt) | barra de direção ajustável com travamento longitudinal. | |
| YU58600A (sh) | Oblik vi 5,6-dihloro-2-(izopropilamino)-1-(beta-l-ribofuranozil)-1h-benzimidazola | |
| ZA200105473B (en) | Utilisation of 2-substituted 1,2-benzisothiazole derivatives and 3-substituted tetrahydropyridopyrimidinone derivatives for the prophylaxis and therapy of cerebral ischaemia. | |
| MXPA02005649A (es) | Nuevas combinaciones terapeuticas de (s)-2 -(bencilamino -metil)-2, 3, 8, 9-tetrahidro-7h -1, 4-dioxino(2-3 -e]indol-8 -ona y agentes neurolepticos para el tratamiento o prevencion de trastornos psicoticos. | |
| PL355113A1 (en) | Novel fusidic acid derivatives | |
| WO2001004090A3 (en) | Neurotrophic tetrahydroisoquinolines and tetrahydrothienopyridines, and related compositions and methods | |
| SI1086695T1 (en) | Antiviral compositions comprising yohimbine as active principle | |
| WO2000016753A3 (de) | Verwendung von nucleosiden, nucleobasen und deren derivaten zum herabsetzen thrombocytopenischer nebenwirkungen von cytostatika |